- Report
- February 2025
- 315 Pages
Global
From €4270EUR$4,799USD£3,759GBP
- Report
- January 2025
- 456 Pages
Global
From €4405EUR$4,950USD£3,877GBP
- Report
- August 2025
- 191 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Report
- October 2025
- 285 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 370 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 372 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 373 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 380 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 282 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- September 2025
- 250 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Report
- February 2025
- 200 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Report
- June 2025
- 400 Pages
Global
From €4404EUR$4,949USD£3,877GBP
- Report
- April 2025
- 125 Pages
United States
From €2892EUR$3,250USD£2,546GBP
- Report
- April 2024
- 183 Pages
Global
From €4004EUR$4,500USD£3,525GBP
- Report
- January 2024
- 200 Pages
Global
From €3693EUR$4,150USD£3,251GBP
- Book
- August 2021
- 312 Pages
Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more
